Taisho Files Domestic Application In Japan For SGLT2 Inhibitor Luseogliflozin
This article was originally published in PharmAsia News
Executive Summary
Taisho Pharmaceutical Holdings filed a domestic application for the approval of new hypoglycemic agent TS-071 (luseogliflozin) April 18.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.